IE37774B1 - Compositions for inhibiting mobilization of calcium phosphate in animal tissue - Google Patents
Compositions for inhibiting mobilization of calcium phosphate in animal tissueInfo
- Publication number
- IE37774B1 IE37774B1 IE93573A IE93573A IE37774B1 IE 37774 B1 IE37774 B1 IE 37774B1 IE 93573 A IE93573 A IE 93573A IE 93573 A IE93573 A IE 93573A IE 37774 B1 IE37774 B1 IE 37774B1
- Authority
- IE
- Ireland
- Prior art keywords
- hydroxycholecalciferol
- acid
- dihydroxycholecalciferol
- hydroxy
- trans
- Prior art date
Links
- 229910000389 calcium phosphate Inorganic materials 0.000 title abstract 2
- 239000001506 calcium phosphate Substances 0.000 title abstract 2
- 235000011010 calcium phosphates Nutrition 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title abstract 2
- -1 phenylethenyl Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 239000003872 25-hydroxy-cholecalciferol Substances 0.000 abstract 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- OAEHUEZTKKWVAX-VTVWKFFSSA-N (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol Chemical compound C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C OAEHUEZTKKWVAX-VTVWKFFSSA-N 0.000 abstract 1
- LAEKPCQYMVJVAK-PBWGLAFFSA-N (1s,3e,4s)-3-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C LAEKPCQYMVJVAK-PBWGLAFFSA-N 0.000 abstract 1
- DFTADKFLALRADR-UHFFFAOYSA-N (3,3,4,4,5,5-hexafluoro-2-phosphonocyclopenten-1-yl)phosphonic acid Chemical compound OP(O)(=O)C1=C(P(O)(O)=O)C(F)(F)C(F)(F)C1(F)F DFTADKFLALRADR-UHFFFAOYSA-N 0.000 abstract 1
- QOWCBCXATJITSI-ZLNGONTQSA-N (6r)-6-[(1r,3as,4e,7ar)-4-[(2z)-2-[(5s)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-1-yl]-2-methylheptane-1,2-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(O)CO)C)=C\C=C1\C[C@@H](O)CCC1=C QOWCBCXATJITSI-ZLNGONTQSA-N 0.000 abstract 1
- GIXFALHDORQSOQ-UHFFFAOYSA-N 2,4,6,8-tetrahydroxy-1,3,5,7,2$l^{5},4$l^{5},6$l^{5},8$l^{5}-tetraoxatetraphosphocane 2,4,6,8-tetraoxide Chemical compound OP1(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)O1 GIXFALHDORQSOQ-UHFFFAOYSA-N 0.000 abstract 1
- FCKJYANJHNLEEP-SRLFHJKTSA-N 24,25-dihydroxycholecalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-SRLFHJKTSA-N 0.000 abstract 1
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 abstract 1
- KJKIIUAXZGLUND-UHFFFAOYSA-N 25-Hydroxyergocalciferol Natural products C1CCC2(C)C(C(C=CC(C)C(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C KJKIIUAXZGLUND-UHFFFAOYSA-N 0.000 abstract 1
- KJKIIUAXZGLUND-ICCVIKJNSA-N 25-hydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-ICCVIKJNSA-N 0.000 abstract 1
- JWUBBDSIWDLEOM-ZMHTYULMSA-N 5,6-trans-25-hydroxyvitamin D3 Chemical compound C([C@@H]([C@]1(CCC2)C)[C@@H](CCCC(C)(C)O)C)CC1\C2=C/C=C1\C[C@H](O)CCC1=C JWUBBDSIWDLEOM-ZMHTYULMSA-N 0.000 abstract 1
- QYSXJUFSXHHAJI-FVUVGDFOSA-N 5,6-trans-vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1/C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-FVUVGDFOSA-N 0.000 abstract 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 abstract 1
- 235000021318 Calcifediol Nutrition 0.000 abstract 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 abstract 1
- YDONNITUKPKTIG-UHFFFAOYSA-N [Nitrilotris(methylene)]trisphosphonic acid Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CP(O)(O)=O YDONNITUKPKTIG-UHFFFAOYSA-N 0.000 abstract 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 abstract 1
- 229960002535 alfacalcidol Drugs 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 150000001340 alkali metals Chemical class 0.000 abstract 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 1
- 150000001342 alkaline earth metals Chemical class 0.000 abstract 1
- 230000001749 antrachitic effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 abstract 1
- 229910001385 heavy metal Inorganic materials 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 229910052738 indium Inorganic materials 0.000 abstract 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000006187 pill Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 abstract 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1401548 Pharmaceutical compositions PROCTER & GAMBLE CO 8 June 1973 [8 June 1972 17 May 1973] 27457/73 Heading A5B Pharmaceutical compositions for inhibiting mobilisation of calcium phosphate in animal tissue useful in the treatment of osteoporosis and Paget's disease comprises (1) at least one polyphosphonate selected from the compounds wherein each R is H or CH 2 OH and n is an integer of from 3 to 10 wherein R 1 is H, C 1-20 alkyl, C 2-20 alkenyl, aryl (e.g. phenyl or naphthyl), phenylethenyl, benzyl, halogen (e.g. Cl, Br, or F), hydroxy, amino, substituted amino (e.g. dimethylamino, diethylamino, N-hydroxy-N-ethylamino or acetylamino), -CH 2 COOH, -CH 2 PO 3 H 2 , -CH- (PO 3 H 2 )(OH) or -[CH 2 C(PO 3 H 2 ) 2 ] n -H wherein n is 1 to 15, and R 2 is hydrogen, C 1-4 alkyl, amino, benzyl, halogen, hydroxyl, -CH 2 COOH, -CH 2 PO 3 H 2 , or -CH 2 CH 2 PO 3 H 2 , wherein n is from 3 to 9, wherein each R 3 is hydrogen or C 1-4 alkyl, wherein n is from 2 to 4, wherein X and Y are each hydrogen or hydroxy or a pharmaceutically acceptable salt thereof e.g. an alkali metal (Na or K), alkaline earth metal (Ca or Mg), non-toxic heavy metal (stannous or indium), ammonium or substituteed ammonium (mono-, di- or triethanolamine) salts, and (2) at least one antirachitic compound selected from vitamin D 2 , vitamin D 3 , dihydroxytachysterol 2 , dihydrotachysterol 3 , 25-hydroxydihydrotachysterol 3 , 25-hydroxyergocalciferol, 25-hydroxycholecalciferol, 1α, 25-. dihydroxycholecalciferol, 5, 6-trans-cholecalciferol, 5, 6-trans-25-hydroxycholecalciferol, 24- nor-25-hydroxycholecalciferol, 24-nor-5, 6-trans 25-hydroxycholecalciferol, 21, 25-dihydroxycholecalciferol, 25, 26-dihydroxycholecalciferol, 24, 25-dihydroxycholecalciferol, and 1α- hydroxycholecalciferol. The polyphosphonate is preferably ethane-1-hydroxy-1, 1-diphosphonic acid, dichloromethandiphosphonic acid, tris(phosphonomethyl)amine, methanecyclohexylhydroxydiphosphonic acid 3, 3, 4, 4, 5, 5- hexafluoro-1, 2-diphosphonocyclopent-1-ene, cyclic tetraphosphonic acid, ethene-1, 2-dicarboxy-1-phosphonic acid or ethane-1, 2-dicarboxy-1, 2-diphosphonic acid. The compositions may be administered orally or parenterally in the form of solutions, elixiers, capsules, tablets, or pills.
[GB1401548A]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26093972A | 1972-06-08 | 1972-06-08 | |
| US36135473A | 1973-05-17 | 1973-05-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE37774L IE37774L (en) | 1973-12-08 |
| IE37774B1 true IE37774B1 (en) | 1977-10-12 |
Family
ID=26948280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE93573A IE37774B1 (en) | 1972-06-08 | 1973-06-08 | Compositions for inhibiting mobilization of calcium phosphate in animal tissue |
Country Status (8)
| Country | Link |
|---|---|
| AU (1) | AU474216B2 (en) |
| CA (1) | CA1007987A (en) |
| DE (2) | DE2328234C2 (en) |
| FR (1) | FR2187292B1 (en) |
| GB (1) | GB1401548A (en) |
| IE (1) | IE37774B1 (en) |
| NL (1) | NL176747C (en) |
| PH (1) | PH9853A (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2553963A1 (en) * | 1975-12-01 | 1977-06-08 | Henkel & Cie Gmbh | Medicaments for treating calcium metabolism disorders - contg. calcitonin and a phosphonic acid or cyclohexane-hexacarboxylic acid |
| DE2553962A1 (en) * | 1975-12-01 | 1977-06-08 | Henkel & Cie Gmbh | Medicaments for treating calcium metabolism disorders - contg. calcitonin and a phosphonic acid or cyclohexane-hexacarboxylic acid |
| JPS603045B2 (en) * | 1976-04-19 | 1985-01-25 | 中外製薬株式会社 | Method for producing 1α-hydroxyvitamin D soft capsules |
| AU2649977A (en) * | 1976-07-15 | 1979-01-04 | Procter & Gamble | Pharmaceutical composition |
| DE3147189A1 (en) * | 1981-11-27 | 1983-06-01 | Siemens AG, 1000 Berlin und 8000 München | Tension relief for a cable which is to be held inside a test plug |
| IT1201087B (en) * | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS |
| DE3540150A1 (en) * | 1985-11-13 | 1987-05-14 | Boehringer Mannheim Gmbh | NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH9776A (en) * | 1967-12-11 | 1976-03-17 | M Francis | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use |
| CA952432A (en) * | 1968-03-04 | 1974-08-06 | The Procter And Gamble Company | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue |
| US3584125A (en) * | 1968-12-23 | 1971-06-08 | Procter & Gamble | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue |
-
1973
- 1973-06-01 PH PH14686A patent/PH9853A/en unknown
- 1973-06-02 DE DE19732328234 patent/DE2328234C2/en not_active Expired
- 1973-06-02 DE DE19732366498 patent/DE2366498C2/de not_active Expired
- 1973-06-07 CA CA173,483A patent/CA1007987A/en not_active Expired
- 1973-06-07 FR FR7320810A patent/FR2187292B1/fr not_active Expired
- 1973-06-07 AU AU56624/73A patent/AU474216B2/en not_active Expired
- 1973-06-08 GB GB2745773A patent/GB1401548A/en not_active Expired
- 1973-06-08 IE IE93573A patent/IE37774B1/en unknown
- 1973-06-08 NL NL7308017A patent/NL176747C/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2187292A1 (en) | 1974-01-18 |
| AU474216B2 (en) | 1976-07-15 |
| CA1007987A (en) | 1977-04-05 |
| NL176747C (en) | 1985-06-03 |
| DE2366498A1 (en) | 1982-09-23 |
| DE2328234C2 (en) | 1983-03-10 |
| PH9853A (en) | 1976-04-13 |
| AU5662473A (en) | 1974-12-12 |
| DE2366498C2 (en) | 1987-08-20 |
| NL176747B (en) | 1985-01-02 |
| DE2328234A1 (en) | 1974-01-03 |
| IE37774L (en) | 1973-12-08 |
| GB1401548A (en) | 1975-07-16 |
| NL7308017A (en) | 1973-12-11 |
| FR2187292B1 (en) | 1976-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3683080A (en) | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue | |
| US3678154A (en) | Oral compositions for calculus retardation | |
| US4134969A (en) | Method of treatment of calcium disorders using aminoalkane-diphosphonic acids | |
| US3488419A (en) | Oral compositions for calculus retardation | |
| US4230700A (en) | Methods for inhibiting mobilization of calcium phosphate in animal tissue | |
| US4330537A (en) | Compositions for inhibiting mobilization of calcium phosphate in animal tissue | |
| US3965254A (en) | Compositions for the treatment of calcific tumors | |
| US3941772A (en) | Azacycloalkane-2,2-diphosphonic acids | |
| US3988443A (en) | Azacycloalkane-2,2-diphosphonic acids | |
| US5366965A (en) | Regimen for treatment or prophylaxis of osteoporosis | |
| US3983227A (en) | Dry mixture containing diphosphonates and a stannous salt useful in the preparation of Tc99M containing bone scanning agents | |
| JP2515929B2 (en) | Macrocyclic aminophosphonic acid complex, its production, formulation and use | |
| US3962433A (en) | Method of treatment of calcium disorders using phosphonoalkane-polycarboxylic acids | |
| US3925456A (en) | Cyclic aminophosphonic acids | |
| EP0054997B1 (en) | Anti-arthritic compositions containing gold salts and organophosphonates | |
| NZ332314A (en) | Oral pharmaceutical preparation containing ibandronate or salts thereof in the form of an inner section containing the active ingredient surrounded by a coating free of the active ingredient | |
| US4086334A (en) | Composition and method for the treatment of disorders of calcium metabolism | |
| EP0833643A4 (en) | Anhydrous alendronate monosodium salt formulations | |
| IE37774B1 (en) | Compositions for inhibiting mobilization of calcium phosphate in animal tissue | |
| US3584124A (en) | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue | |
| US3920837A (en) | Method of treatment of calcium disorders using cyclohexane-hexacarboxylic acid | |
| JPS6133117A (en) | Kit for treating bone disease | |
| NL8200298A (en) | PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF OSTEOPATHIES. | |
| GB1254465A (en) | Composition for inhibiting anomalous deposition and mobilization of calcium phosphate in human tissue | |
| US4634691A (en) | Method for inhibiting tumor metastasis |